Moderate to Severe Plaque Psoriasis: Clinical Trials

41 trials for Moderate to Severe Plaque Psoriasis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

24 completed, 4 not yet recruiting, 4 recruiting, 3 active not recruiting. 14 Phase 3, 9 Phase 2, 7 Phase 1, 4 Phase 4, 1 Not applicable.

By phase and status

PhaseTrialsStatus
Phase 314Completed 8, Active not recruiting 2, Not yet recruiting 2, Recruiting 1, Terminated 1
Phase 29Completed 6, Not yet recruiting 2, Active not recruiting 1
Phase 17Completed 3, Unknown 2, Recruiting 1, Withdrawn 1
Phase 44Withdrawn 2, Completed 1, Not yet recruiting 1
Not applicable1Recruiting 1

Follow Moderate to Severe Plaque Psoriasis: new trials by email Literature Review of Moderate to Severe Plaque Psoriasis trials Research Report on Moderate to Severe Plaque Psoriasis

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Phase 2 Study of HS-20118 to Evaluate the Efficacy and Safety in Participant With Moderate-to-Severe Plaque Psoriasis
HS-20118, Placebo - Moderate to Severe Plaque Psoriasis
Phase 2Not yet recruitingJiangsu Hansoh Pharmaceutical Co., Ltd.1202026-08-062026-08-14
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase Ⅲ Study to Evaluate the Efficacy and Safety of WD-890 Tablets for the Treatment of Moderate to Severe Plaque Psoriasis
Drug:WD-890, Drug: placebo - Moderate to Severe Plaque Psoriasis
Phase 3RecruitingZhejiang Wenda Pharma Technology LTD.3752026-03-182026-06-29
A Clinical Study Evaluating the Efficacy and Safety of CMS-D001 Tablets in the Treatment of Adult Patients With Moderate to Severe Plaque-type Psoriasis
CMS-D001 50mg, CMS-D001 100mg, Placebo - Moderate to Severe Plaque Psoriasis
Phase 2 / Phase 3Not yet recruitingDermavon Holdings Limited5402026-03-032026-02-25
A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)
Bimekizumab - Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis
Phase 1RecruitingUCB Biopharma SRL202025-11-052026-09-18
A Study to Evaluate Effectiveness and Safety of a TYK2 Inhibitor in Subjects With Moderate to Severe Plaque Psoriasis
Tyk2 inhibitor, Placebo - Plaque Psoriasis, Moderate to Severe Plaque Psoriasis
Not applicableRecruitingUsynova Pharmaceuticals Ltd.1402025-10-212025-11-18
A Phase III Study of SYHX1901 Tablets in the Treatment of Moderate to Severe Plaque Psoriasis
SYHX1901 - Moderate to Severe Plaque Psoriasis
Phase 3Not yet recruitingCSPC Ouyi Pharmaceutical Co., Ltd.5002025-06-012025-04-30
A Trial Comparing SHR-1139 Injection With Placebo in Patients With Moderate-to-severe Plaque Psoriasis
SHR-1139 Injection, SHR-1139 Injection Placebo - Moderate to Severe Plaque Psoriasis
Phase 2Active not recruitingGuangdong Hengrui Pharmaceutical Co., Ltd1452025-03-282025-07-14
Phase IV Study: Vunakizumab Efficacy and Safety in Moderate-to-severe Plaque Psoriasis
Drug group:vunakizumab (IL-17A inhibitor) - Moderate to Severe Plaque Psoriasis
RecruitingFirst Hospital of China Medical University15162025-02-172025-05-14
Phase IV Study: Vunakizumab Efficacy and Safety in Moderate-to-severe Plaque Psoriasis
Vunakizumab (IL-17A inhibitor) - Moderate to Severe Plaque Psoriasis
Phase 4Not yet recruitingSuzhou Suncadia Biopharmaceuticals Co., Ltd.15642025-02-012025-01-16
A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis
bimekizumab - Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis
Phase 3Active not recruitingUCB Biopharma SRL892024-07-292026-07-17
A Phase I Clinical Trial of Single Subcutaneous Injection or Intravenous Infusion of SHR-1139 Injection in Healthy Chinese Subjects and Multiple Subcutaneous Injections in Patients With Moderate-to-severe Plaque Psoriasis
SHR-1139 Injections, SHR-1139 Injections Placebo - Moderate to Severe Plaque Psoriasis
Phase 1CompletedGuangdong Hengrui Pharmaceutical Co., Ltd642024-06-262026-01-28
A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents From 6 Years to Less Than 18 Years of Age With Moderate to Severe Plaque Psoriasis
bimekizumab, ustekinumab, placebo - Moderate to Severe Plaque Psoriasis
Phase 3Active not recruitingUCB Biopharma SRL1762024-06-252026-09-18
Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ICP-488 in Patients with Moderate to Severe Plaque Psoriasis
ICP-488 Tablets, ICP-488 Placebo - Moderate to Severe Plaque Psoriasis
Phase 2CompletedBeijing InnoCare Pharma Tech Co., Ltd.1292024-01-042025-02-28
Safety and Efficacy of TLL018 in Patients With Plaque Psoriasis
TLL018 tablets - Moderate to Severe Plaque Psoriasis
Phase 1CompletedHangzhou Highlightll Pharmaceutical Co., Ltd732022-06-102023-09-22
2 Years Prospective Study to Collect Real-life Data on the Retention, Quality of Life, Effectiveness and Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis
secukinumab - Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis
CompletedNovartis Pharmaceuticals1272022-03-252026-10-23
Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of CT303 in Patients With Psoriasis
CT303 - Moderate to Severe Plaque Psoriasis
Phase 1UnknownGC Cell Corporation242021-10-252022-03-18
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Korean Study Participants With Moderate to Severe Plaque Psoriasis
bimekizumab, Placebo - Moderate to Severe Plaque Psoriasis
Phase 3CompletedUCB Biopharma SRL472021-09-272025-03-18
Study of NDI-034858 in Participants With Moderate to Severe Plaque Psoriasis
NDI-034858 study drug, Placebo - Moderate to Severe Plaque Psoriasis
Phase 2CompletedTakeda2592021-08-112023-09-28
A Study to Compare SB17 (Proposed Ustekinumab Biosimilar) to Stelara® in Subject With Moderate to Severe Plaque Psoriasis
Stelara® (Ustekinumab), SB17 (Proposed Ustekinumab Biosimilar) - Psoriasis, Moderate to Severe Plaque Psoriasis
Phase 3CompletedSamsung Bioepis Co., Ltd.5032021-07-062025-05-25
A Study to Assess the Pharmacokinetics, Safety, and Efficacy of Two Doses of Bimekizumab in Adolescent Study Participants With Moderate to Severe Plaque Psoriasis
bimekizumab - Moderate to Severe Plaque Psoriasis
Phase 2CompletedUCB Biopharma SRL412021-04-062026-08-03

Showing 20 of 41. Sign in to see all of them.

Narrower conditions

Psoriasis (9)  ·  Arthritis, Psoriatic (3)  ·  Axial Spondyloarthritis (1)  ·  Hidradenitis Suppurativa (1)  ·  Non-Radiographic Axial Spondyloarthritis (1)  ·  Spondylitis, Ankylosing (1)

Broader conditions

Skin Diseases (12)  ·  Skin Diseases, Papulosquamous (12)  ·  Skin and Connective Tissue Diseases (12)  ·  Arthritis (3)  ·  Bone Diseases (3)  ·  Joint Diseases (3)  ·  Musculoskeletal Diseases (3)  ·  Psoriasis (3)  ·  Spinal Diseases (3)  ·  Spondylarthritis (3)  ·  Spondylarthropathies (3)  ·  Spondylitis (3)  ·  Ankylosis (2)  ·  Axial Spondyloarthritis (1)  ·  Bacterial Infections (1)

Interventions

bimekizumab (6)  ·  Adalimumab (3)  ·  Ustekinumab (3)  ·  briakinumab (3)  ·  brodalumab (3)  ·  secukinumab (2)  ·  Etanercept (1)  ·  Injections (1)  ·  Midazolam (1)  ·  Sodium Chloride (1)  ·  Tablets (1)

Sponsors

AbbVie (prior sponsor, Abbott) (6)  ·  UCB Biopharma SRL (6)  ·  Guangdong Hengrui Pharmaceutical Co., Ltd (2)  ·  Kyowa Kirin Co., Ltd. (2)  ·  Novartis Pharmaceuticals (2)  ·  AbbVie (1)  ·  Abbott (1)  ·  Bausch Health Americas, Inc. (1)  ·  Beijing InnoCare Pharma Tech Co., Ltd. (1)  ·  Biocad (1)  ·  CSPC Ouyi Pharmaceutical Co., Ltd. (1)  ·  Dermavon Holdings Limited (1)  ·  Diamant Thaci (1)  ·  First Hospital of China Medical University (1)  ·  Fresenius Kabi SwissBioSim GmbH (1)

Countries

United States (14)  ·  China (11)  ·  Germany (9)  ·  Canada (8)  ·  Poland (8)  ·  Hungary (6)  ·  Czechia (5)  ·  South Korea (5)  ·  Estonia (4)  ·  Russia (4)  ·  Spain (4)  ·  France (3)  ·  Australia (2)  ·  Austria (2)  ·  Belgium (2)

Top investigators

Martin Kaul, MD (2)  ·  David A Williams, MD (1)  ·  Diamant Thaci, Prof. (1)  ·  Jaka Brumen (1)  ·  Martin Okun, MD (1)  ·  Robert D Arbeit, MD (1)  ·  Roman Ivanov, PhD (1)  ·  Seongjin Jo (1)

Results publications

PMID 21574984, PMID 26138406, PMID 26422722, PMID 26547109, PMID 30328108, PMID 30471012, PMID 32207067, PMID 33891379, PMID 34060012, PMID 34606048, PMID 35544084, PMID 36689515, PMID 36751950, PMID 37950894, PMID 39167366, PMID 39264399, PMID 39328126, PMID 39578348, PMID 40286813, PMID 40886218, PMID 41060492, PMID 41359217, PMID 41580158, PMID 41800601, PMID 42143206

NIH funding

2023 (3), 2016 (2), 2015 (1)